



CNEA

KEY CHOICE

Gain expertise, confidence,
and recognition in your
clinical practice.

2022 VIRTUAL TOUR THE INSTITUTE OF CARDIOVASCULAR EXCELLENCE

COMPREHENSIVE CARDIOVASCULAR PHARMACOLOGY: FOR EXCELLENCE IN PRACTICE 2 DAY CONFERENCE

Topics:

- ⇒ Impacting Cardiac Output
- ⇒ Evidence Based ACS Tx Updates
- ⇒ Algorithms for Dyslipidemia
- ⇒ Diabetes Meds Beyond Diabetes
- ⇒ Pharmacology to Stop Smoking
- ⇒ Risk Reduction in PAD
- ⇒ Complexities in Heart Failure
- ⇒ Antiarrhythmic Safety
- ⇒ HTN Management
- ⇒ Medications & Renal Function
- ⇒ Solutions to Nonadherence
- ⇒ Medication Safety

DATES AND TIMES FOR LIVE VIRTUAL CONFERENCES:

January 6th & 7th: 8am to 4:30pm CST

January 11th & 12th: 8am to 4:30pm MST

Instructors: Karen Marzlin & Cynthia Webner

Can't Attend One of our Virtual Conferences?

Order the recorded version now at a discounted price and view at your own pace. The program will be available to you by January 24th.

We take vast and complex information, synthesize it for you, and present relevant and practical applications.

14.0 CE and 14.0 Pharmacology CE

Day 1 Objectives:

1. Compare pharmacologic treatment options for the short term and long-term treatment of STEMI, NSTEMI-ACS and stable coronary artery disease.
2. Contrast the use of fibrinolytics, anticoagulants and antiplatelet therapy in patients with CAD.
3. Contrast the impact of various lipid lowering agents in achieving guideline recommended lipid goals.
4. Identify strategies for lipid management in the patient experiencing statin intolerance.
5. Examine pharmacologic treatment strategy options with oral diabetic agents in the CV patient with type II diabetes.
6. Determine the appropriate use of SGLT inhibitors in reducing cardiovascular risk in the patient with DM.
7. Evaluate medication driven treatment strategy plans for tobacco cessation.
8. Evaluate medication driven treatment strategy plans for tobacco cessation.
9. Develop strategies to improve patient medication adherence through understanding patient barriers.

Day 2 Objectives:

1. Differentiate risk /benefits of antiarrhythmics medications based on Vaughan Williams classification.
2. Contrast the pharmacologic treatment options for AF with a rate control versus a rhythm control strategy.
3. Examine the appropriateness of the new oral anticoagulants for stroke prevention in AF.
4. Utilizing evidence-based (EB) guidelines, develop a systematic approach to the assessment and treatment of hypertension.
5. Integrate concepts of acute kidney injury failure and chronic kidney disease into pharmacologic treatment strategies.
6. Discuss EB pharmacologic treatment strategies for HFrEF and HFpEF.
7. Prioritize the use of EB medications during periods of decompensated heart failure.
8. Outline strategies for initiation and up titration of medications in patients with heart failure.
9. Determine practice changes that could improve patient safety with medication reconciliation.

**CNEA IS AN PROVIDER APPROVED BY THE
CALIFORNIA BOARD OF REGISTERED NURS-
ING PROVIDER NUMBER 15714**